Global Pharmaceutical CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Pharmaceutical CDMO Market is presumed to reach the market size of nearly USD 351.64 Billion by 2032 from USD 179.47 Billion in 2023 with a CAGR of 7.76% under the study period 2024-2032.

A pharmaceutical CDMO (Contract Development and Manufacturing Organization) provides comprehensive services to pharmaceutical companies, including drug development, manufacturing, and packaging. These organizations support pharmaceutical firms from the initial stages of drug formulation to large-scale production and distribution. CDMOs offer expertise in various aspects of the drug lifecycle, including clinical trials, regulatory compliance, and quality control. Partnering with a CDMO allows pharmaceutical companies to leverage specialized knowledge and infrastructure, accelerating time-to-market and reducing costs while ensuring high safety and efficacy standards in drug production.

MARKET DYNAMICS

The growth of the pharmaceutical CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for pharmaceutical outsourcing, as companies seek to streamline operations, lower costs, and focus on core competencies such as research and marketing. The complexity of drug development and the need for specialized skills and equipment has led many pharmaceutical companies to rely on CDMOs for development and manufacturing processes. Additionally, the rise in biologics and biosimilar production has significantly boosted the demand for Pharmaceutical CDMOs, as these complex molecules require specialized manufacturing capabilities. Technological advancements in manufacturing processes, such as continuous manufacturing and single-use technologies, have further enhanced the appeal of CDMOs.

The growing trend towards personalized medicine and niche therapeutics also contributes to market growth, as these require flexible and scalable production solutions that CDMOs can provide. Moreover, regulatory pressures and the need for compliance with stringent quality standards make CDMOs an attractive option for pharmaceutical companies looking to mitigate risks and ensure product quality. The expanding pharmaceutical industry in emerging markets and increased investment in drug development drive the pharmaceutical CDMO market. However, regulatory compliance challenges and competitive pressures may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmaceutical CDMO. The growth and trends of Pharmaceutical CDMO industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmaceutical CDMO market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Infectious Diseases
Oncology
Neurological Disorders

By Workflow

Commercial
Clinical

By Product

Synthesis
Manufacturing
Drug
API

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmaceutical CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmaceutical CDMO market include WuXi AppTec, Catalent Inc., AbbVie Contract Manufacturing, Lonza Group AG, Evonik Industries AG, Patheon, Siegfried Holding AG, Recipharm AB, Aenova Group, CordenPharma, Jubilant Life Sciences Ltd., Almac Group, Piramal Pharma Solutions, Cambrex Corporation, Fareva. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114744

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PHARMACEUTICAL CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Workflow
- 3.7.3 Market Attractiveness Analysis By Product
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Infectious Diseases Historic and Forecast Sales By Regions
5.4. Oncology Historic and Forecast Sales By Regions
5.5. Neurological Disorders Historic and Forecast Sales By Regions

6. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY WORKFLOW

6.1. Overview By Workflow
6.2. Historical and Forecast Data Analysis By Workflow
6.3. Commercial Historic and Forecast Sales By Regions
6.4. Clinical Historic and Forecast Sales By Regions

7. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY PRODUCT

7.1. Overview By Product
7.2. Historical and Forecast Data Analysis By Product
7.3. Synthesis Historic and Forecast Sales By Regions
7.4. Manufacturing Historic and Forecast Sales By Regions
7.5. Drug Historic and Forecast Sales By Regions
7.6. API Historic and Forecast Sales By Regions

8. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL CDMO COMPANIES

9.1. Pharmaceutical CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PHARMACEUTICAL CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. WuXi AppTec
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Catalent Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. AbbVie Contract Manufacturing
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Lonza Group AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Evonik Industries AG
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Patheon
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Siegfried Holding AG
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Recipharm AB
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Aenova Group
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. CordenPharma
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Jubilant Life Sciences Ltd.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Almac Group
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Piramal Pharma Solutions
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Cambrex Corporation
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Fareva
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies